Literature DB >> 8671587

Differential requirements for co-stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens.

Z Yi-qun1, R J Joost van Neerven, A Kasran, M de Boer, J L Ceuppens.   

Abstract

The interaction between CD28 on T cells with CD80 (B7-1) and CD86 (B7-2) on APCs is considered to be of critical importance for primary T cell activation both in vivo and in vitro. The relative importance of this co-stimulatory signal in memory T cell activation is, however, less clear, and was therefore studied by in vitro experiments on T cell responses to soluble recall antigens using peripheral blood mononuclear cells or T cell clones. Our data demonstrate that B7-2 represents the major co-stimulatory signal for the activation of resting peripheral blood memory T cells with recall antigens, as evidenced by the effects of anti-B7-1 and anti-B7-2 on T cell proliferation as well as on IL-2 and INF-gamma production. Since CTLA-4-lg and anti-CD28 Fab fragments had similar inhibitory effects to the combination of anti-B7-1 plus anti B7-2, the involvement of a third co-stimulatory CD28/CTLA-4 ligand is unlikely. Despite the strong effects of B7-blocking agents, a variable fraction of the memory T cells was resistant to inhibition. Moreover, T cell clones or in vitro preactivated T cells could efficiently be restimulated by soluble atigens on autologous APCs in the absence of B7-1 or B7-2 co-stimulation. These data show that most memory T cells that are freshly isolated from the blood are still dependent on CD28 triggering for their activation. However, recently activated T cells can apparently bypass the requirement for B7 and use other co-stimulatory signals for reactivation, a finding with important implications for the development of immunosuppressive strategies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8671587     DOI: 10.1093/intimm/8.1.37

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  10 in total

Review 1.  Immunomodulation by interference with co-stimulatory molecules: therapeutic perspectives in asthma.

Authors:  S E Burastero; G A Rossi
Journal:  Thorax       Date:  1999-06       Impact factor: 9.139

2.  Blocking B7 and CD40 co-stimulatory molecules decreases antiviral T cell activity.

Authors:  J Vermeiren; J L Ceuppens; H Haegel-Kronenberger; M De Boer; L Boon; S W Van Gool
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

3.  Non-responsiveness to hepatitis B surface antigen vaccines is not caused by defective antigen presentation or a lack of B7 co-stimulation.

Authors:  I Desombere; T Cao; Y Gijbels; G Leroux-Roels
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

4.  Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells.

Authors:  A E Lovett-Racke; J L Trotter; J Lauber; P J Perrin; C H June; M K Racke
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

5.  Analysis of the costimulatory requirements for generating human virus-specific in vitro T helper and effector responses.

Authors:  V Blazevic; C M Trubey; G M Shearer
Journal:  J Clin Immunol       Date:  2001-07       Impact factor: 8.317

6.  GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes.

Authors:  Vissia Viglietta; Sally C Kent; Tihamer Orban; David A Hafler
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

7.  The Toll-like receptor 1/2 agonists Pam(3) CSK(4) and human β-defensin-3 differentially induce interleukin-10 and nuclear factor-κB signalling patterns in human monocytes.

Authors:  Nicholas T Funderburg; Julie K Jadlowsky; Michael M Lederman; Zhimin Feng; Aaron Weinberg; Scott F Sieg
Journal:  Immunology       Date:  2011-10       Impact factor: 7.397

8.  Immune response induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines.

Authors:  J Carlos Arroyo; Fernando Gabilondo; Luis Llorente; Marco A Meraz-Ríos; Carmen Sánchez-Torres
Journal:  J Clin Immunol       Date:  2004-01       Impact factor: 8.317

9.  Human β Defensin-3 Increases CD86 Expression on Monocytes by Activating the ATP-Gated Channel P2X7.

Authors:  Anthony B Lioi; Brian M Ferrari; George R Dubyak; Aaron Weinberg; Scott F Sieg
Journal:  J Immunol       Date:  2015-09-28       Impact factor: 5.422

Review 10.  TCR cross-reactivity and allorecognition: new insights into the immunogenetics of allorecognition.

Authors:  L J D'Orsogna; D L Roelen; I I N Doxiadis; F H J Claas
Journal:  Immunogenetics       Date:  2011-12-03       Impact factor: 2.846

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.